 |
Sunderland Joint Formulary |
 |
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust |
|
| Results |
Looking for Adalimumab found 28 matches
|
| Formulary |
BNF Category |
| |
Adalimumab
(See 10.01.03 for preparations)
|
Cytokine inhibitors - 01.05.03
|
| |
Adalimumab
(Humira®)
|
Cytokine modulators - 10.01.03
|
| |
Links Link to Drug Section  Link to document |
|
NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab (10.01.03)
|
|
NICE TA143: Ankylosing spondylitis - adalimumab, etanercept and infliximab (10.01.03)
|
|
NICE TA146: Adalimumab for the treatment of adults with psoriasis (10.01.03)
|
|
NICE TA146: Psoriasis - adalimumab (13.05.03)
|
|
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
|
|
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
|
|
NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
|
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (10.01.03)
|
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (10.01.03)
|
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (10.01.03)
|
|
|
|
|
|
